Details
Category: Volume 07 Issue 06 June 2019
Hits: 1019

Title: Low-Dose Morphine versus High-Dose Tramadol for management of moderate cancer pain: a comparative study

Authors: Subrata Chatterjee, Shantanu Ghosh

 DOI: https://dx.doi.org/10.18535/jmscr/v7i6.116

Abstract

Introduction: The treatment of pain in cancer patients following the guidelines outlined by World Health Organisation has been found to be feasible and effective. The guidelines recommend a sequential three-step analgesic ladder for treatment of pain but there is a lack of conclusive data regarding the management of moderate pain with step II weak opioids or low-dose step III strong opioids.

Methods: In total, Eighty two adult patients with moderate cancer pain were included in this randomised controlled study to receive either low dose morphine or high dose tramadol. The primary outcome was the number of responder patients where the response was defined as patients with a 20% reduction in pain intensity on the numerical rating scale.

Results: The primary outcome occurred in 85.8% of the low-dose morphine and in 57.8% of the tramadol group (odds risk, 4.41; 95% CI,P<.001). The percentage of responder patients was found to be higher in the low-dose morphine group in this study. Clinically meaningful (>30%) and highly meaningful (>50%) pain reduction from baseline was significantly higher in the low-dose morphine group (P <.001). Due to inadequate analgesia a change in the treatment process occurred more frequently in the tramadol group. The general condition of patients, which was based on the Edmonton Symptom Assessment System (ESAS) overall symptom score, was better in the morphine group. Adverse effects were similar in both groups.
Conclusion: Moderate cancer pain can be managed significantly better by low dose morphine than tramadol with early onset of action and similar level of adverse effects.

Keywords: Moderate cancer pain, tramadol, morphine.

References

  1. WHO: Cancer Pain Relief. Geneva, Switzerland, WHO, 1986
  2. WHO: Cancer Pain Relief (ed 2). Geneva, Switzerland, WHO, 1996
  3. Schug SA, Zech D, Do¨ rr U: Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 5:27-32,1990
  4. Brooks DJ, Gamble W, Ahmedzai S. A regional survey of opioid use by patients receiving specialist palliative care. Palliat Med 1995;9:229–38.
  5. Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC. Efficacy and safety of nonsteroidal anti-inflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994;12:2756–65.
  6. Freynhagen R, Zenz M, Strumpf M. WHO StepII—Clinical reality or a didactic instrument? [InGerman]. Der Schmerz 1994;8:210–5.
  7. Sichetti D, Bandieri E, Romero M, et al; ECAD Working Group: Impact of setting of care on pain management in patients with cancer: a multicentre cross-sectional study. Ann Oncol 21:2088-93,2010
  8. Costantini M, Ripamonti C, Beccaro M, et al: Prevalence, distress, management, and relief of pain during the last 3 months of cancer patients’ life.Results of an Italian mortality follow-back survey. Ann Oncol 20:729-35, 2009
  9. Apolone G, Corli O, Caraceni A, et al; Cancer Pain Outcome Research Study Group (CPOR SG)Investigators: Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer 100:1566-74, 2009
  10. Deandrea S, Montanari M, Moja L, Apolone G: Prevalence of under treatment in cancer pain. A review of published literature. Ann Oncol 19:1985-91, 2008
  11. Di MaioM, Gridelli C, Gallo C, et al: Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer 90:2288-96, 2004
  12. Greco MT, Roberto A, Corli O, et al: Quality of cancer pain management: an update of a systematic review of under treatment of patients with cancer.J Clin Oncol 32:4149-54, 2014
  13. Zenz M, Willweber-Strumpf A: Opiophobia and cancer pain in Europe. Lancet 341:1075-6.
  14. Radbruch L, Grond S, Lehmann KA. A risk–benefit assessment of tramadol in the management of pain. Drug Safety 1996;15:8–29.
  15. Brema F, Pastorino G, Martini MC, Gottlieb A,Luzzani M, Libretti A, Sacca L, Cigolari S. Oral tramadol and buprenorphine in tumour pain: an Italian multicentre trial. Int J Clin Pharmacol Res 1996;16:109–16.
  16. Osipova NA, Novikov GA, Beresnev VA, Loseva A. Analgesic effect of tramadol in cancer patients with chronic pain: a comparison with prolongedaction morphine sulfate. Curr Ther Res 1991;50:812–21.
  17. Rodrigues N, Rodrigues Pereira E. Tramadol in cancer pain. Curr Ther Res 1989;46:1142–8.
  18. Tawfik MO, Elborolossy K, Nasr F. Tramadol hydrochloride in the relief of cancer pain: a double blind comparison against sustained release morphine.Pain 1990;(Suppl. 5):S377.
  19. Wilder-Smith CH, Schimke J, Osterwalder B, Senn HJ. Oral tramadol, a m-opioid agonist and monoaminereuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 1994;5:141–6.
  20. Serlin RC, Mendoza TR, Nakamura Y, et al: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277-84, 1995
  21. Stockler MR, Wilcken NR: Why is management of cancer pain still a problem? J Clin Oncol 30:1907-8, 2012
  22. Bruera E, Palmer JL, Bosnjak S, et al: Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study. J Clin Oncol 22:185-92, 2004
  23. Bruera E, Kuehn N, Miller MJ, et al; The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6-9, 1991
  24. Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al: Reduction of cancer-related fatigue with dexamethasone: A double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31:3076-82, 2013
  25. Ripamonti CI, Bandieri E, Pessi MA, et al: The Edmonton Symptom Assessment System (ESAS) as a screening tool for depression and anxiety in non-advanced patients with solid or haematological malignancies on cure or follow-up. Support Care Cancer 22:783-93, 2014
  26. Dworkin RH, Turk DC, Farrar JT, et al: IMMPACT: Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113:9-19, 2005
  27. Ventafridda V, Tamburini M, Caraceni A, et al: A validation study of the WHO method for cancer pain relief. Cancer 59:850-6, 1987
  28. Marinangeli F, Ciccozzi A, Leonardis M, et al: Use of strong opioids in advanced cancer pain: A randomized trial. J Pain Symptom Manage 27:409-16, 2004
  29. Maltoni M, Scarpi E, Modonesi C, et al: A validation study of the WHO analgesic ladder: A two-step vs three-step strategy. Support Care Cancer 13: 888-94, 2005
  30. Mercadante S, Porzio G, Ferrera P, et al: Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 31:242-47, 2006
  31. Goodwin PJ, Bruera E, Stockler M: Pain in patients with cancer. J Clin Oncol 32:1637-9, 2014
  32. Caraceni A, Hanks G, Kaasa S, et al; European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC): Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58-e68, 2012
  33. Ripamonti CI, Santini D, Maranzano E, et al; ESMO Guidelines Working Group: Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 23: vii 139-54, 2012
  34. Hui D, Shamieh O, Paiva CE, et al: Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: a prospective, multicentre study. Cancer 121:3027-35, 2015

Corresponding Author

Dr Shantanu Ghosh

Address: 127A APC Road, Kolkata, West Bengal, India, Pin: 700006